AdAlta Ltd. (AU:1AD) has released an update.
AdAlta Limited is gearing up for clinical activities with strategic appointments and partnerships. The company has secured a non-binding term sheet for its AdCella unit and aims to advance its AD-214 drug candidate for fibrotic diseases. AdAlta’s bolstered leadership and improved cash position signal promising progress in their ‘East to West’ cellular immunotherapy strategy.
For further insights into AU:1AD stock, check out TipRanks’ Stock Analysis page.